Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis.

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relamorelin (Primary)
  • Indications Diabetic gastroparesis
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Rhythm

    • Most Recent Events

    • 20 May 2013 Results from the type 1 diabetic cohort were presented at the Digestive Disease Week 2013 conference and published in Clinical Gastroenterology and Hepatology, according to a Rhythm Pharmaceuticals media release.
    • 06 Sep 2012 Primary endpoint gastric emptying half-time for solids has been met.
    • 22 May 2012 Status changed from recruiting to completed, based on information from a Rhythm Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top